logo
Plus   Neg
Share
Email

Rigel Pharmaceuticals Inc. (RIGL) Plunged To A New Low On Fostamatinib News

Rigel Pharmaceuticals Inc. (RIGL) and partner AstraZeneca (AZN) reported clinical trial results for their oral treatment for rheumatoid arthritis, fostamatinib, which failed to meet one of the main objectives.

Rigel Pharmaceuticals gapped open sharply lower Thursday and fell further around mid-morning. Shares finished down by 2.92 at $5.51 on the highest volume of the year. The stock plummeted to a new low for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT